Dutch Minister calls for "drugmaker pride"

28 April 2009

The Netherlands' Minister for Economic Affairs, Maria van der Hoeven, has called on drugmakers to position themselves in the public eye better  and to take more pride in their achievements. The call comes in an  article published by Nefarma, the national research-based pharmaceutical  association, in its monthly newsletter Nefarma&.

Ms van der Hoeven praised the R&D contribution of the pharmaceutical  sector to the Netherlands' economy, equal to over 10% of the country's  total R&D investment and 15% of drugmakers' turnover on average.  However, she also warned that the international perception of the  Netherlands as a place to carry out drug research is not as high as it  should be and that the Ministry of Economic Affairs and the Ministry of  Education would be presenting proposals to improve intellectual  cooperation between businesses and academia.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight